HRA-Pharma Profile: Women's Health Pharma Specialist

TL;DR

Bloomberg profile covers Laboratoire HRA-Pharma SAS, a French firm making drugs and devices for women's reproductive health and endocrinology.
Company based in Châtillon, France, founded in 1996, acquired by Perrigo in 2022 for €1.8 billion.
Focuses on emergency contraception like ellaOne and serves customers in over 50 countries worldwide.

The story at a glance

The Bloomberg page profiles Laboratoire HRA-Pharma SAS (ticker 3613996Z:FP), which develops and manufactures pharmaceutical products for women, including drugs and devices for reproductive health and endocrinology. It serves customers worldwide from its headquarters in Châtillon, near Paris. This company page provides a basic overview without recent news or financial metrics.[[1]](https://www.bloomberg.com/profile/company/3613996Z:FP)

Key points

Develops products for women's health, with a strong emphasis on emergency contraception (e.g., ellaOne with ulipristal acetate) and other reproductive areas.
Key brands include Compeed for blister care, Mederma for scar care, and treatments for rare endocrine diseases like adrenal cancer (Lysodren).
Founded in 1996, headquartered at 200 Avenue de Paris, 92320 Châtillon, France; around 51-200 employees pre-acquisition.
Acquired by Perrigo Company plc in May 2022 for €1.8 billion ($2.1 billion) to expand in consumer self-care.
Operates in over 50 countries via subsidiaries in 11 European nations and global partnerships; its rare diseases unit faces potential sale to Esteve for up to €275 million.
No market cap, revenue, or performance data shown on the profile page.[[2]](https://www.hra-pharma.com/)[[3]](https://chemdmart.com/company-profile/laboratoire-hra-pharma-sas)[[4]](https://investor.perrigo.com/2021-09-08-Perrigo-to-Acquire-Leading-Consumer-Self-Care-Company,-HRA-Pharma)

Details and context

Laboratoire HRA-Pharma started as a specialist in unmet needs in reproductive health, becoming Europe's leader in emergency contraception. It expanded into dermatology and rare diseases through acquisitions like Mederma.

Perrigo's 2022 purchase integrated HRA's OTC brands to build a global self-care portfolio, though the rare diseases affiliate may soon divest to Esteve pending approvals.

The Bloomberg profile lacks depth—no executives listed (former CEO David Wright), financials, or updates—focusing only on core business description.[[5]](https://investor.perrigo.com/2024-04-25-Perrigo-Receives-Binding-Offer-to-Divest-its-HRA-Pharma-Rare-Diseases-Business-for-up-to-EUR275-Million)

Why it matters

This profile highlights a key player in women's health pharma amid growing demand for accessible contraception and self-care products. Investors or researchers tracking Perrigo's portfolio or European pharma get a starting point, though details are sparse. Watch for rare diseases unit sale closure in 2024 or new product launches like OTC Opill in the US.